Literature DB >> 30097236

Immune check-point in cervical cancer.

F De Felice1, C Marchetti2, I Palaia3, R Ostuni3, L Muzii3, V Tombolini1, P Benedetti Panici3.   

Abstract

Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CTLA-4; Cervical cancer; Immune check-point; Immunotherapy; Ipilimumab; Nivolumab; PD-1; Pembrolizumab

Mesh：

Substances：

Year:  2018        PMID： 30097236     DOI： 10.1016/j.critrevonc.2018.06.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  16 in total

Review 1.  Immune check-point in endometrial cancer.

Authors:  Francesca De Felice; Claudia Marchetti; Vincenzo Tombolini; P Benedetti Panici
Journal:  Int J Clin Oncol       Date:  2019-05-02       Impact factor: 3.402

2.  Machine Learning of Dose-Volume Histogram Parameters Predicting Overall Survival in Patients with Cervical Cancer Treated with Definitive Radiotherapy.

Authors:  Zhiyuan Xu; Li Yang; Qin Liu; Hao Yu; Longhua Chen
Journal:  J Oncol       Date:  2022-06-14       Impact factor: 4.501

3.  Immunotherapy in cervical cancer: the advent of precision medicine.

Authors:  Francesca De Felice; Claudia Marchetti; Anna Fagotti; Giovanni Scambia
Journal:  Ann Transl Med       Date:  2020-06

Review 4.  Immune checkpoint inhibitors in the treatment of virus-associated cancers.

Authors:  Peipei Gao; Cordelle Lazare; Canhui Cao; Yifan Meng; Ping Wu; Wenhua Zhi; Shitong Lin; Juncheng Wei; Xiaoyuan Huang; Ling Xi; Gang Chen; Junbo Hu; Ding Ma; Peng Wu
Journal:  J Hematol Oncol       Date:  2019-06-10       Impact factor: 17.388

5.  A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer.

Authors:  Peijie Chen; Yuting Gao; Si Ouyang; Li Wei; Min Zhou; Hua You; Yao Wang
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

Review 6.  Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment.

Authors:  Francesca De Felice; Daniela Musio; Vincenzo Tombolini
Journal:  J Pers Med       Date:  2021-05-10

Review 7.  Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review.

Authors:  Nathália Alves Araújo de Almeida; Camilla Rodrigues de Almeida Ribeiro; Jéssica Vasques Raposo; Vanessa Salete de Paula
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

8.  Identifying Potential Neoantigens for Cervical Cancer Immunotherapy Using Comprehensive Genomic Variation Profiling of Cervical Intraepithelial Neoplasia and Cervical Cancer.

Authors:  Chaohui Bao; Na An; Hong Xie; Ling Xu; Boping Zhou; Jun Luo; Wanqiu Huang; Jian Huang
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

Review 9.  RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review.

Authors:  Peter A van Dam; Yannick Verhoeven; Julie Jacobs; An Wouters; Wiebren Tjalma; Filip Lardon; Tim Van den Wyngaert; Jonatan Dewulf; Evelien Smits; Cécile Colpaert; Hans Prenen; Marc Peeters; Martin Lammens; Xuan Bich Trinh
Journal:  Int J Mol Sci       Date:  2019-05-02       Impact factor: 5.923

10.  Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.

Authors:  Clint T Allen; Sunmin Lee; Scott M Norberg; Damian Kovalovsky; Hong Ye; Paul E Clavijo; Siwen Hu-Lieskovan; Richard Schlegel; Jeffrey Schlom; Julius Strauss; James L Gulley; Jane Trepel; Christian S Hinrichs
Journal:  J Immunother Cancer       Date:  2019-05-03       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.